BG8 LewisY (F3), MMab
For In Vitro Diagnostic Use
Description
Blood group antigens have been examined as potential discriminators between Pulmonary Adenocarcinoma (PACA) and Epithelioid Mesothelioma (EM). LewisY is the only one of these that appears to have some merit. BG8 is raised from the SK-LU-3 lung cancer line and is able to distinguish between PACA and EM. Studies of 231 cases of PACA and 197 cases of EM have shown that sensitivity and specificity for PACA were both 93%. It has been reported that sensitivity of nonmesothelial antigens for Adenocarcinoma is organ dependent, with BG8 Lewis antibody performing at 98% in the breast cancer group, and 100% in the lung cancer group. The specificity of the nonmesothelial (non-EM) antigens for adenocarcinoma was 98% for BG8. It has been concluded using logical regression analysis that a three-antibody immunohistochemical panel including Calretinin, BG8, and MOC-31 would provide 96% sensitivity and specificity for distinguishing EM from Adenocarcinoma in a variety of sources (lung, ovary, breast, stomach).
Synonymes
bg8 lewis y, anti-bg8 lewisy, anti-bg8 lewis y, anti-bg8-lewis-y, anti-bgly, bgly antibody
Caractéristiques
- Type
- Mouse Monoclonal
- Clone
- F3
- Isotype
- IgM
- Réactivité
- Paraffin, Frozen
- Localisation
- Cytoplasmic
- Contrôle
- Placenta, Tonsil, Pancreas, Cervix, Bladder TCC, Lung Adenocarcinoma
- Usage prévu
- For In Vitro Diagnostic Use
Intéressé par ce produit ?
Indiquez la référence et le conditionnement souhaités, nous revenons vers vous rapidement.
BIO SB